Cargando…

Problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement

Objective: The problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement was investigated and analyzed in order to provide reference for the regulatory agencies to formulate policies. Methods: A questionnaire survey was conducted to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wen, Xu, Qingwen, Peng, Jing, Zhang, Xiaotong, Chen, Lu, Wu, Yilai, Yang, Kui, Luan, Jiajie, Liu, Xiaoyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10513935/
https://www.ncbi.nlm.nih.gov/pubmed/37745061
http://dx.doi.org/10.3389/fphar.2023.1233491
_version_ 1785108623892938752
author Zhang, Wen
Xu, Qingwen
Peng, Jing
Zhang, Xiaotong
Chen, Lu
Wu, Yilai
Yang, Kui
Luan, Jiajie
Liu, Xiaoyun
author_facet Zhang, Wen
Xu, Qingwen
Peng, Jing
Zhang, Xiaotong
Chen, Lu
Wu, Yilai
Yang, Kui
Luan, Jiajie
Liu, Xiaoyun
author_sort Zhang, Wen
collection PubMed
description Objective: The problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement was investigated and analyzed in order to provide reference for the regulatory agencies to formulate policies. Methods: A questionnaire survey was conducted to collect the problems encountered by 329 Chinese medical institutions in implementing the national centralized drug procurement and the corresponding suggestions provided by relevant experts. Statistical analysis was performed to identify differences in the themes and the number of collected problems, further revealing the relevance to the region in which the medical institutions is located. Result: 1360 problems and suggestions were collected from 329 Chinese medical institutions that located in North (19.15%), Northeast (5.78%), East (33.43%), Central (10.03%), South (9.73%), Southwest (14.89%), and Northwest China (6.99%). There was statistically significant difference in the number of collected problems and suggestions between regions (p < 0.001). Furthermore, the content of gathered problems and suggestions involves in 15 themes including system construction, organizational system and work responsibilities, reasonable measurement and reporting of procurement volume et al. These themes that these medical institutions are focusing on are mainly centered on the supply guarantee (15%), reasonable measurement and reporting of procurement volume (11.40%) and guarantee measures for clinical priority use (9.48%) of drugs with national centralized procurement. Meanwhile, we found that problems regarding the supply guarantee of drugs with national centralized procurement displayed significant difference between regions (p = 0.0096). Conclusion: Chinese medical institutions are facing great challenges in implementing the national centralized drug procurement. The scientific study and judgment of the current situation and the construction of corresponding solution require a precise classification of the problems encountered by medical institutions in the process of implementing the national centralized drug procurement policy, which is of great practical significance for deepening the reform of the medical and health system.
format Online
Article
Text
id pubmed-10513935
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105139352023-09-23 Problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement Zhang, Wen Xu, Qingwen Peng, Jing Zhang, Xiaotong Chen, Lu Wu, Yilai Yang, Kui Luan, Jiajie Liu, Xiaoyun Front Pharmacol Pharmacology Objective: The problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement was investigated and analyzed in order to provide reference for the regulatory agencies to formulate policies. Methods: A questionnaire survey was conducted to collect the problems encountered by 329 Chinese medical institutions in implementing the national centralized drug procurement and the corresponding suggestions provided by relevant experts. Statistical analysis was performed to identify differences in the themes and the number of collected problems, further revealing the relevance to the region in which the medical institutions is located. Result: 1360 problems and suggestions were collected from 329 Chinese medical institutions that located in North (19.15%), Northeast (5.78%), East (33.43%), Central (10.03%), South (9.73%), Southwest (14.89%), and Northwest China (6.99%). There was statistically significant difference in the number of collected problems and suggestions between regions (p < 0.001). Furthermore, the content of gathered problems and suggestions involves in 15 themes including system construction, organizational system and work responsibilities, reasonable measurement and reporting of procurement volume et al. These themes that these medical institutions are focusing on are mainly centered on the supply guarantee (15%), reasonable measurement and reporting of procurement volume (11.40%) and guarantee measures for clinical priority use (9.48%) of drugs with national centralized procurement. Meanwhile, we found that problems regarding the supply guarantee of drugs with national centralized procurement displayed significant difference between regions (p = 0.0096). Conclusion: Chinese medical institutions are facing great challenges in implementing the national centralized drug procurement. The scientific study and judgment of the current situation and the construction of corresponding solution require a precise classification of the problems encountered by medical institutions in the process of implementing the national centralized drug procurement policy, which is of great practical significance for deepening the reform of the medical and health system. Frontiers Media S.A. 2023-08-30 /pmc/articles/PMC10513935/ /pubmed/37745061 http://dx.doi.org/10.3389/fphar.2023.1233491 Text en Copyright © 2023 Zhang, Xu, Peng, Zhang, Chen, Wu, Yang, Luan and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhang, Wen
Xu, Qingwen
Peng, Jing
Zhang, Xiaotong
Chen, Lu
Wu, Yilai
Yang, Kui
Luan, Jiajie
Liu, Xiaoyun
Problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement
title Problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement
title_full Problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement
title_fullStr Problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement
title_full_unstemmed Problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement
title_short Problems and challenges encountered by Chinese medical institutions in implementing the national centralized drug procurement
title_sort problems and challenges encountered by chinese medical institutions in implementing the national centralized drug procurement
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10513935/
https://www.ncbi.nlm.nih.gov/pubmed/37745061
http://dx.doi.org/10.3389/fphar.2023.1233491
work_keys_str_mv AT zhangwen problemsandchallengesencounteredbychinesemedicalinstitutionsinimplementingthenationalcentralizeddrugprocurement
AT xuqingwen problemsandchallengesencounteredbychinesemedicalinstitutionsinimplementingthenationalcentralizeddrugprocurement
AT pengjing problemsandchallengesencounteredbychinesemedicalinstitutionsinimplementingthenationalcentralizeddrugprocurement
AT zhangxiaotong problemsandchallengesencounteredbychinesemedicalinstitutionsinimplementingthenationalcentralizeddrugprocurement
AT chenlu problemsandchallengesencounteredbychinesemedicalinstitutionsinimplementingthenationalcentralizeddrugprocurement
AT wuyilai problemsandchallengesencounteredbychinesemedicalinstitutionsinimplementingthenationalcentralizeddrugprocurement
AT yangkui problemsandchallengesencounteredbychinesemedicalinstitutionsinimplementingthenationalcentralizeddrugprocurement
AT luanjiajie problemsandchallengesencounteredbychinesemedicalinstitutionsinimplementingthenationalcentralizeddrugprocurement
AT liuxiaoyun problemsandchallengesencounteredbychinesemedicalinstitutionsinimplementingthenationalcentralizeddrugprocurement